Disease Category Listing By Location Liver Cancer

Clinical Trial Search

Liver Cancer

Click on a link below the country name to see trial details in a specific location

Australia

MELBOURNE ML18469
A Study of Avastin (Bevacizumab) and Xeloda (Capecitabine) in Patients With Advanced or Metastatic Liver Cancer Completed

Belgium

BRUXELLES NP27884
A Study of RO5137382 (GC33) in Patients with Advanced or Metastatic Hepatocellular Carcinoma Recruiting
GENT NP27884
A Study of RO5137382 (GC33) in Patients with Advanced or Metastatic Hepatocellular Carcinoma Recruiting

China

BEIJING ML18269
A Study of Xeloda (Capecitabine) and PEGASYS in Treatment-Naive Patients With Advanced Liver Cancer Completed
GUANGZHOU ML18269
A Study of Xeloda (Capecitabine) and PEGASYS in Treatment-Naive Patients With Advanced Liver Cancer Completed

France

ANGERS NP27884
A Study of RO5137382 (GC33) in Patients with Advanced or Metastatic Hepatocellular Carcinoma Recruiting
NICE NP27884
A Study of RO5137382 (GC33) in Patients with Advanced or Metastatic Hepatocellular Carcinoma Recruiting
TOULOUSE NP27884
A Study of RO5137382 (GC33) in Patients with Advanced or Metastatic Hepatocellular Carcinoma Recruiting
VILLEJUIF NP27884
A Study of RO5137382 (GC33) in Patients with Advanced or Metastatic Hepatocellular Carcinoma Recruiting

FRANCE

Clichy NP27884
A Study of RO5137382 (GC33) in Patients with Advanced or Metastatic Hepatocellular Carcinoma Recruiting
Grenoble NP27884
A Study of RO5137382 (GC33) in Patients with Advanced or Metastatic Hepatocellular Carcinoma Recruiting
MARSEILLE NP27884
A Study of RO5137382 (GC33) in Patients with Advanced or Metastatic Hepatocellular Carcinoma Recruiting
Paris NP27884
A Study of RO5137382 (GC33) in Patients with Advanced or Metastatic Hepatocellular Carcinoma Recruiting
VANDOEUVRE-LES-NANCY NP27884
A Study of RO5137382 (GC33) in Patients with Advanced or Metastatic Hepatocellular Carcinoma Recruiting

Germany

FRANKFURT AM MAIN NP27884
A Study of RO5137382 (GC33) in Patients with Advanced or Metastatic Hepatocellular Carcinoma Recruiting
FREIBURG NP27884
A Study of RO5137382 (GC33) in Patients with Advanced or Metastatic Hepatocellular Carcinoma Recruiting
HEIDELBERG NP27884
A Study of RO5137382 (GC33) in Patients with Advanced or Metastatic Hepatocellular Carcinoma Recruiting
TÜBINGEN NP27884
A Study of RO5137382 (GC33) in Patients with Advanced or Metastatic Hepatocellular Carcinoma Recruiting

GERMANY

Berlin NP27884
A Study of RO5137382 (GC33) in Patients with Advanced or Metastatic Hepatocellular Carcinoma Recruiting
Leipzig NP27884
A Study of RO5137382 (GC33) in Patients with Advanced or Metastatic Hepatocellular Carcinoma Recruiting
Munich NP27884
A Study of RO5137382 (GC33) in Patients with Advanced or Metastatic Hepatocellular Carcinoma Recruiting

Hong Kong

HONG KONG NP27884
A Study of RO5137382 (GC33) in Patients with Advanced or Metastatic Hepatocellular Carcinoma Recruiting
HONG KONG ML18469
A Study of Avastin (Bevacizumab) and Xeloda (Capecitabine) in Patients With Advanced or Metastatic Liver Cancer Completed
HONG KONG ML21358
A Study of Avastin (Bevacizumab) and TACE Treatment in Patients With Liver Cancer. Completed

HONG KONG

Pokfulam NP27884
A Study of RO5137382 (GC33) in Patients with Advanced or Metastatic Hepatocellular Carcinoma Recruiting
Hong Kong ML21358
A Study of Avastin (Bevacizumab) and TACE Treatment in Patients With Liver Cancer. Completed
HONG KONG ML18469
A Study of Avastin (Bevacizumab) and Xeloda (Capecitabine) in Patients With Advanced or Metastatic Liver Cancer Completed
HONG KONG ML21358
A Study of Avastin (Bevacizumab) and TACE Treatment in Patients With Liver Cancer. Completed

ITALY

Benevento NP27884
A Study of RO5137382 (GC33) in Patients with Advanced or Metastatic Hepatocellular Carcinoma Recruiting
Milano NP27884
A Study of RO5137382 (GC33) in Patients with Advanced or Metastatic Hepatocellular Carcinoma Recruiting
Padova NP27884
A Study of RO5137382 (GC33) in Patients with Advanced or Metastatic Hepatocellular Carcinoma Recruiting
ROMA NP27884
A Study of RO5137382 (GC33) in Patients with Advanced or Metastatic Hepatocellular Carcinoma Recruiting

JAPAN

Kanagawa NP27884
A Study of RO5137382 (GC33) in Patients with Advanced or Metastatic Hepatocellular Carcinoma Recruiting
Kanazawa NP27884
A Study of RO5137382 (GC33) in Patients with Advanced or Metastatic Hepatocellular Carcinoma Recruiting
Kashiwa NP27884
A Study of RO5137382 (GC33) in Patients with Advanced or Metastatic Hepatocellular Carcinoma Recruiting
Osaka NP27884
A Study of RO5137382 (GC33) in Patients with Advanced or Metastatic Hepatocellular Carcinoma Recruiting
Tokyo NP27884
A Study of RO5137382 (GC33) in Patients with Advanced or Metastatic Hepatocellular Carcinoma Recruiting

KOREA, REPUBLIC OF

Busan NP27884
A Study of RO5137382 (GC33) in Patients with Advanced or Metastatic Hepatocellular Carcinoma Recruiting
Seoul NP27884
A Study of RO5137382 (GC33) in Patients with Advanced or Metastatic Hepatocellular Carcinoma Recruiting

New Zealand

AUCKLAND NP27884
A Study of RO5137382 (GC33) in Patients with Advanced or Metastatic Hepatocellular Carcinoma Recruiting

Philippines

MANILA ML21213
A Study of Tarceva (Erlotinib) and Avastin (Bevacizumab) in Patients With Advanced or Metastatic Liver Cancer. Completed

Republic of Korea

GYEONGGI-DO NP27884
A Study of RO5137382 (GC33) in Patients with Advanced or Metastatic Hepatocellular Carcinoma Recruiting
SEOUL ML21213
A Study of Tarceva (Erlotinib) and Avastin (Bevacizumab) in Patients With Advanced or Metastatic Liver Cancer. Completed

Singapore

SINGAPORE NP27884
A Study of RO5137382 (GC33) in Patients with Advanced or Metastatic Hepatocellular Carcinoma Recruiting
SINGAPORE BP25497
A Dose-Finding and Exploratory Study of RO5323441 in Combination With Sorafenib in Patients With Hepatocellular Carcinoma Completed
SINGAPORE ML18469
A Study of Avastin (Bevacizumab) and Xeloda (Capecitabine) in Patients With Advanced or Metastatic Liver Cancer Completed

Spain

BARCELONA NP27884
A Study of RO5137382 (GC33) in Patients with Advanced or Metastatic Hepatocellular Carcinoma Recruiting
MADRID NP27884
A Study of RO5137382 (GC33) in Patients with Advanced or Metastatic Hepatocellular Carcinoma Recruiting
SANTANDER NP27884
A Study of RO5137382 (GC33) in Patients with Advanced or Metastatic Hepatocellular Carcinoma Recruiting
ZARAGOZA NP27884
A Study of RO5137382 (GC33) in Patients with Advanced or Metastatic Hepatocellular Carcinoma Recruiting

SPAIN

Barcelona, BARCE NP27884
A Study of RO5137382 (GC33) in Patients with Advanced or Metastatic Hepatocellular Carcinoma Recruiting
Madrid, MADRI NP27884
A Study of RO5137382 (GC33) in Patients with Advanced or Metastatic Hepatocellular Carcinoma Recruiting

Taiwan

TAICHUNG NP27884
A Study of RO5137382 (GC33) in Patients with Advanced or Metastatic Hepatocellular Carcinoma Recruiting
TAIPEI NP27884
A Study of RO5137382 (GC33) in Patients with Advanced or Metastatic Hepatocellular Carcinoma Recruiting
TAOYUAN NP27884
A Study of RO5137382 (GC33) in Patients with Advanced or Metastatic Hepatocellular Carcinoma Recruiting
KUEISHAN ML18269
A Study of Xeloda (Capecitabine) and PEGASYS in Treatment-Naive Patients With Advanced Liver Cancer Completed
KUEISHAN ML18469
A Study of Avastin (Bevacizumab) and Xeloda (Capecitabine) in Patients With Advanced or Metastatic Liver Cancer Completed
KUEISHAN ML21213
A Study of Tarceva (Erlotinib) and Avastin (Bevacizumab) in Patients With Advanced or Metastatic Liver Cancer. Completed
TAINAN ML18269
A Study of Xeloda (Capecitabine) and PEGASYS in Treatment-Naive Patients With Advanced Liver Cancer Completed
TAINAN ML21213
A Study of Tarceva (Erlotinib) and Avastin (Bevacizumab) in Patients With Advanced or Metastatic Liver Cancer. Completed
TAIPEI ML18469
A Study of Avastin (Bevacizumab) and Xeloda (Capecitabine) in Patients With Advanced or Metastatic Liver Cancer Completed
TAIPEI ML21213
A Study of Tarceva (Erlotinib) and Avastin (Bevacizumab) in Patients With Advanced or Metastatic Liver Cancer. Completed

TAIWAN

Kaohsiung NP27884
A Study of RO5137382 (GC33) in Patients with Advanced or Metastatic Hepatocellular Carcinoma Recruiting
Taichung NP27884
A Study of RO5137382 (GC33) in Patients with Advanced or Metastatic Hepatocellular Carcinoma Recruiting
Tainan NP27884
A Study of RO5137382 (GC33) in Patients with Advanced or Metastatic Hepatocellular Carcinoma Recruiting
Taipei NP27884
A Study of RO5137382 (GC33) in Patients with Advanced or Metastatic Hepatocellular Carcinoma Recruiting

Thailand

BANGKOK ML18269
A Study of Xeloda (Capecitabine) and PEGASYS in Treatment-Naive Patients With Advanced Liver Cancer Completed
CHIANG MAI ML18269
A Study of Xeloda (Capecitabine) and PEGASYS in Treatment-Naive Patients With Advanced Liver Cancer Completed
SONGKHLA ML18269
A Study of Xeloda (Capecitabine) and PEGASYS in Treatment-Naive Patients With Advanced Liver Cancer Completed

U.S.A.

HOUSTON, TX NP27884
A Study of RO5137382 (GC33) in Patients with Advanced or Metastatic Hepatocellular Carcinoma Recruiting
SEATTLE, WA NP27884
A Study of RO5137382 (GC33) in Patients with Advanced or Metastatic Hepatocellular Carcinoma Recruiting

United Kingdom

LONDON NP27884
A Study of RO5137382 (GC33) in Patients with Advanced or Metastatic Hepatocellular Carcinoma Recruiting

UNITED KINGDOM

Bebington NP27884
A Study of RO5137382 (GC33) in Patients with Advanced or Metastatic Hepatocellular Carcinoma Recruiting

UNITED STATES

Los Angeles, CA NP27884
A Study of RO5137382 (GC33) in Patients with Advanced or Metastatic Hepatocellular Carcinoma Recruiting
Bethesda, MD NP27884
A Study of RO5137382 (GC33) in Patients with Advanced or Metastatic Hepatocellular Carcinoma Recruiting
Ann Arbor, MI NP27884
A Study of RO5137382 (GC33) in Patients with Advanced or Metastatic Hepatocellular Carcinoma Recruiting
Detroit, MI NP27884
A Study of RO5137382 (GC33) in Patients with Advanced or Metastatic Hepatocellular Carcinoma Recruiting
St. Louis, MO NP27884
A Study of RO5137382 (GC33) in Patients with Advanced or Metastatic Hepatocellular Carcinoma Recruiting
New York, NY NP27884
A Study of RO5137382 (GC33) in Patients with Advanced or Metastatic Hepatocellular Carcinoma Recruiting
Nashville, TN NP27884
A Study of RO5137382 (GC33) in Patients with Advanced or Metastatic Hepatocellular Carcinoma Recruiting

About This Registry

This registry serves as a global repository for information on ongoing Roche Pharmaceuticals Phase II to Phase IV clinical studies, Phase I studies in patients and Roche Diagnostics interventional studies on advanced diagnostic products.

> For more information

Common Questions